您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > ABT-199
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ABT-199
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ABT-199图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
2mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
ABT-199 (ABT-199; GDC-0199) 是一种高效、选择性和口服生物可利用的 Bcl-2 抑制剂,Ki 小于 0.01 nM。 ABT-199 诱导自噬。

Preparation Method

The affinity of ABT-199 for different subtypes of the Bcl-2 family (Ki or IC50) was determined by competitive fluorescence polarization assays using the following peptide probe/protein pairs: F-BAD (1 nM) and Bcl-XL (6 nM),F-bax (1 nM) and Bcl-2 (10 nM), F-Bax (1 nM) and Bcl-W (40 nM), F-NOxa (2 nM) and McL-1 (40 nM),And the affinity of F-Bax (1 nM) and Bcl-2-A1(15 nM) for Bcl-XL was determined by time-resolved fluorescence resonance energy transfer assays.1 nM Tb labeled anti-His antibody,And ABT-199 were mixed for 30 min at room temperature on Envision microplate reader. Fluorescence values were measured using excitation filters at 340/35 nm and emission filters at 520/525 (F-BAK) and 495/510 nm (anti-His antibody labeled with Tb).

Reaction Conditions

ABT-199 with Bcl-2 for 30 min at RT

Applications

ABT-199 has a subnanomolar affinity for BCL-2 (Ki< 0.010 nM) and bound over three orders of magnitude less avidly to BCL-XL (Ki = 48 nM) and BCL-W (Ki = 245 nM) than to BCL-2.

Cell lines

NHL cell lines

Preparation Method

The viability of NHL cell lines was examined after 48 h incubation with increasing concentrations of Navitoclax or ABT-199.

Reaction Conditions

0.01 μM -3.0 μM ABT-199 for 48h

Applications

ABT-199 cell killing was selective and mechanism dependent, BCL2high status is thus a potential predictive marker for sensitivity to ABT-199.

Animal models

Female C.B-17 SCID-beige mice

Preparation Method

All xenograft trials were conducted using ten mice per group, and all mice were ear tagged and monitored individually throughout the studies. ABT-199 was formulated for oral dosing in 60% phosal 50 propylene glycol (PG), 30% polyethylene glycol (PEG) 400 and 10% ethanol. ABT-199 was delivered approximately 2 h before bendamustine or bendamustine plus rituximab.

Dosage form

12.5 mg/kg ABT-199 for 60 days

Applications

After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), ABT-199 caused a maximal tumor growth inhibition (TGImax) of 47% and tumor growth delay (TGD) of 26%.

文献引用
产品描述

Venetoclax (ABT-199, GDC-0199) is a selective inhibitor of Bcl-2 with a K i of 0.01 nM in cell-free assays. Compared to Bcl-XL and Bcl-W more than 4800 times more selective, no inhibitory activity against McL-1[1].

ABT-199 cell killing was selective and mechanism dependent, BCL2high status is thus a potential predictive marker for sensitivity to ABT-199[1].BIM binding to BCL2 correlates with ABT-199 response and further showed that knockout of BIM results in decreased ABT-199 sensitivity. Eexpression of B-cell genes as enriched in ABT-199-sensitive myeloma, although no single gene consistently delineated sensitive and resistant cells[4]. In the ABT-199-resistant OCI-AML3 cell line, CXCL12 promoted an increase in the proportion of cells expressing high levels of embryonic stem cell core transcription factors abrogated by CD44 knockdown[7].The T-ALL cell line LOUCY, which shows a transcriptional program related to immature T-ALL, exhibited high in vitro and in vivo sensitivity for ABT-199 in correspondence with high levels of BCL-2. In addition, ABT-199 showed synergistic therapeutic effects with different chemotherapeutic agents[3].When performed a genome-wide CRISPR knockout screen and found that inactivation of genes involved in mitochondrial translation restored sensitivity to ABT-199 in resistant AML cells. Pharmacologic inhibition of mitochondrial protein synthesis with antibiotics that target the ribosome, including tedizolid and doxycycline, effectively overcame ABT-199 resistance[6].

VU661013 is a novel, potent, selective MCL1 inhibitor. VU661013 was safely combined with ABT-199 for synergy in murine models of AML[3].ABT-199 and 5-Aza act synergistically to kill AML cells in vitro and display combinatorial antitumor activity in vivo[5]. Treatment with ABT-199 alone and in combination is well tolerated, with the most common side effects being neutropenia, infection, and gastrointestinal toxic effects[2].

References:
[1]: Souers AJ, Leverson JD, et,al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6. PMID: 23291630.
[2]: Ramsey HE, Fischer MA, et,al. A Novel MCL1 Inhibitor Combined with ABT-199 Rescues ABT-199-Resistant Acute Myelogenous Leukemia. Cancer Discov. 2018 Dec;8(12):1566-1581. doi: 10.1158/2159-8290.CD-18-0140. Epub 2018 Sep 5. PMID: 30185627; PMCID: PMC6279595.
[3]: Bi C, Zhang X, et,al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017 Apr;102(4):755-764. doi: 10.3324/haematol.2016.159160. Epub 2017 Jan 19. PMID: 28104700; PMCID: PMC5395116.
[4]: Gupta VA, Barwick BG, et,al. ABT-199 sensitivity in multiple myeloma is associated with B-cell gene expression. Blood. 2021 Jul 1;137(26):3604-3615. doi: 10.1182/blood.2020007899. PMID: 33649772; PMCID: PMC8462405.
[5]: Jin S, Cojocari D, et,al. 5-Azacitidine Induces NOXA to Prime AML Cells for ABT-199-Mediated Apoptosis. Clin Cancer Res. 2020 Jul 1;26(13):3371-3383. doi: 10.1158/1078-0432.CCR-19-1900. Epub 2020 Feb 13. PMID: 32054729.
[6]: Sharon D, Cathelin S, et,al. Inhibition of mitochondrial translation overcomes ABT-199 resistance in AML through activation of the integrated stress response. Sci Transl Med. 2019 Oct 30;11(516):eaax2863. doi: 10.1126/scitranslmed.aax2863. PMID: 31666400.
[7]: Yu X, Munoz-Sagredo L, et,al. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor ABT-199 by decreasing CXCL12-driven survival cues. Blood. 2021 Sep 23;138(12):1067-1080. doi: 10.1182/blood.2020006343. PMID: 34115113.